October 2026
2026-10-23 ⚗️ 4 🧬 1 💻 1 🏢 2
Six science items: an oral STING inhibitor, TLR7/8 antagonists cleared of a BRD4 liability, a mouse-model fix for BRD9 PROTACs, solvated ligand-strain calculation, antitubulin pyrroloquinolines, and a BCL9/β-catenin glioma inhibitor. Business: the Lilly–Metis lipid-nanoparticle deal and Isomorphic Labs' valuation talks.
2026-10-22 ⚗️ 6 💻 1 🏢 3
Seven science items: a fumarate-handle TTK degrader, electrophile-first UBE2D2 inhibitors, a selective macrocyclic CDK7 series, PDE4B and MKK3 programs, inhaled DDR inhibitors, and a cofolding benchmark. Business: Roche–Hansoh ADCs, GSK's hepatitis B approval, Roivant's uveitis data.
2026-10-21 ⚗️ 4 💻 1 🏢 1
Five science items today: a hERG-cleaned DCN1–UBE2M inhibitor, a DNA-based CENPB degrader, a single-dose malaria candidate now in phase 1, an interpretable P-gp redesign tool and an FGFR3-selectivity perspective. Business is thin: China's draft curbs on foreign biopharma acquisitions.
2026-10-20 ⚗️ 4 💻 1 🏢 2
Five science items today: PROTAC target engagement reinterpreted through intracellular exposure, a CNS-penetrant PARP1-selective inhibitor, covalent epoxysuccinate PLpro inhibitors, an AlphaLISA screen for ISG15–UBA7, and kinase-inhibitor protonation states. Business: Gilead's oral UC data and Merck KGaA buying Silence.
2026-10-19 ⚗️ 2 💻 1 🏢 1
Three science items today: repurposing approved anticancer drugs as intrinsic photosensitizers, an albumin-delivered iron(III) agent for triple-negative breast cancer, and a web-based covalent docking tool. Business: Lilly expands its Sec61 pact with Gate Bioscience.
2026-10-18 ⚗️ 4 💻 1 🏢 1
Five science items today: de novo MYC binders, a bivalent BPTF inhibitor, a macrocyclic RAB27A binder, pairwise QSAR for potency extrapolation and benzodiazepine antimalarials. Business: Lakefront sells its shelved CAR-T programs to Paul Stoffels' new Armed Cell.
2026-10-17 ⚗️ 6 🧬 2 🏢 3
Eight science items today: an HDAC11 inhibitor for NSCLC, TTBK1/2 probes, brain-penetrant EGFR TKI structures, an oral MRGPRX2 antagonist, allosteric covalent cereblon inhibition, a RhoJ pocket, and two Science Translational Medicine papers (TREM2 agonist, PP2A glue). Business: AstraZeneca–insitro, Merck–Moderna and RevMed's EU nod.
2026-10-16 ⚗️ 8 🏢 5
Eight science items today: a BCL6 PROTAC, a brain-penetrant MTA-cooperative PRMT5 inhibitor, BAX inhibitors, oral SLC6A19 inhibitors, a probe-validity check on Elevenostat, a NaV1.7 probe, Tau-LRP1 screening hits and covalent mitotic inhibitors. Five business items: Roche–Rona, Zealand–Generate, Gilead–Vir, Pfizer–Enodia and Verastem's KRAS G12D data.
2026-10-15 ⚗️ 6 💻 1 🏢 1
Seven science items today: a CHD4 macrocycle study, a G2019S-selective LRRK2 series, cinchona-derived nerve blockers, an oral STAT6 degrader, a GTP-state KRAS G12C inhibitor, covalent SHP2 lysine fragments and a DEL-based ML benchmark. One business item: Sanofi's EU antitrust settlement.
2026-10-14 ⚗️ 8 🏢 1
Eight science items today: an HDAC6 L2-pocket series, a STING inhibitor for pancreatitis, a TFEB inhibitor grown from eltrombopag, an MprB antivirulence series for tuberculosis, a tubulin/HDAC8 dual inhibitor, a PDIA3 antiviral, a peptide-like DEL and a PI4KIIIβ/HDAC dual HCV series. One business item: safety questions around Neurocrine's Vykat XR.
2026-10-13 ⚗️ 5 🧬 1
Six science items today, all small-molecule and degrader work: a non-competitive KDM6B inhibitor, a G protein-biased GPR183 agonist, STK33 male-contraceptive indazoles, a TLR4 PROTAC, VHL-based HDAC6 degraders and dual MOR/D3R opioid ligands. No new business items cleared the bar.
2026-10-12 ⚗️ 6 💻 1 🏢 2
Seven science items today: a G2019S-selective LRRK2 series, a siderophore–ampicillin conjugate, dual BuChE/FAAH inhibitors, an IL-11 antagonist peptide, LasB inhibitors from kinetic target-guided synthesis, masked ASM inhibitors and a binding-energy GNN. Business: Viatris–Pacira and a Life Biosciences glaucoma update.
2026-10-10 ⚗️ 7 💻 1 🏢 2
Eight science items today: Hsp90β-selective inhibitors, a DEL-derived MAGL inhibitor, a DNMT1 PROTAC, an HDAC2-selective compound, ENPP1 and colchicine-site leads, an RL fragment-growing tool and QPCT/L screening. Business: ArriVent's phase 3 miss and argenx's Sjögren's setback.
2026-10-09 ⚗️ 6 🏢 3
Six science items today: a selective ULK1 PROTAC, a clinical-grade PERK inhibitor, an inhaled sGC stimulator, oral POLQ inhibitors, a docking-vs-crystal-structure study and sulfonium echinocandins. Business: Roche's molecular glue deal, Merck's Keytruda SC court setback and Forbion's $2.6B fund.
2026-10-08 ⚗️ 3 💻 1 🏢 2
Four science items today: a dengue NS4B inhibitor design, a BBB-penetrant lanosterol derivative for Alzheimer's, chiral TLR7/8 imidazoquinolines and a PKMYT1 carboxamide patent overview. Business: Caribou's wind-down and AstraZeneca's new Kendall Square R&D site.
2026-10-07 ⚗️ 5 🏢 3
Five science items today: a macrocycle-derived EGFR PROTAC, two PKMYT1/OGG1 chemotypes, HIPK4 cyanoquinolines for male contraception and an NLRP3 inhibitor for colitis. Business: Genentech's $100M AL050 deal, Merck's KRAS G12D license and Lycia's LYTAC IPO filing.
2026-10-06 ⚗️ 4 🏢 4
Four science items today: a single-atom switch that flips NSD2/GSPT1 degrader selectivity, light-activated VEGFR2 inhibitors for the eye, FTO inhibitors for AML and pan-YTHDF m6A reader ligands. Business covers CSL–Alentis, Shionogi's IntraBio buyout, Genmab's Rina-S data and Jaypirca's first-line CLL approval.
2026-10-05 ⚗️ 4 🧬 1 🏢 2
Five science items today: a GSPT1 glue degrader for glioblastoma, a DNA-origami degrader of mutant KRAS mRNA, an ACER2 inhibitor, the first PAPP-A inhibitors and a click-triggered warhead. Business adds Summit's Datroway–ivonescimab collaboration and JCR's Italfarmaco license.
2026-10-04 ⚗️ 4 💻 1 🏢 2
Five science items today, from GPCR-degrading bispecifics and a CD73 inhibitor to soft-drug design, a new docking potential and PROTAC linker scoring, plus two obesity and macrocycle business items: Boehringer/Zealand's survodutide and Novo's Orbis deal.
2026-10-03 ⚗️ 6 💻 1 🏢 1
Seven science items, from a rescued HIV NNRTI lead and selective wild-type KIT inhibitors to covalent MAP2K4/7 targeting, OGT-recruiting chimeras, masked T cell engagers, a new hit-finding library and an oral GLP-1 review, plus Novartis's $7.8B Abogen mRNA T-cell engager license.
2026-10-02 ⚗️ 7 💻 1 🏢 2
Eight science items led by a Nav1.7 pain lead, new HDAC8 and brain-targeted degraders, a p300/CBP perspective and co-folding virtual screening, plus two business stories: Sanofi–Regeneron's $1B antibody expansion and Lilly's amylin–tirzepatide data.
2026-10-01 ⚗️ 6 🏢 4
Six science items, from gut-restricted RXFP4 agonists and covalent GBA2 inhibitors to cereblon PROTAC prodrugs and an open DNA glycosylase screen, plus four deals and setbacks: Novo–Hengrui, AstraZeneca–Summit, Roche's emugrobart exit and Merck's Recarbrio withdrawal.